» Articles » PMID: 11335065

Amyloid Beta Protein 1-40 and 1-42 Levels in Matched Cerebrospinal Fluid and Plasma from Patients with Alzheimer Disease

Overview
Journal Neurosci Lett
Specialty Neurology
Date 2001 May 4
PMID 11335065
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

We quantitated amyloid beta proteins 1-40 (Abeta40) and 1-42 (Abeta42), and alpha1- antichymotrypsin (ACT) in matched cerebrospinal fluid (CSF) and plasma of 50 patients with probable Alzheimer disease, and analyzed the relationships with age, sex, Mini-Mental State Examination (MMSE), and apolipoprotein E phenotype. There was no relation between CSF Abeta40 and Abeta42 levels with those of plasma. CSF and plasma Abeta40 and Abeta42 levels showed no association with age, sex, and MMSE score. There was a significant correlation between CSF ACT and plasma ACT levels. The data suggest that plasma ACT crosses the blood-brain barrier. However, a lack of correlation between CSF Abeta40 and Abeta42 levels with those of plasma suggests that Abeta in CSF and plasma originates from different sources.

Citing Articles

Clearance and transport of amyloid β by peripheral monocytes correlate with Alzheimer's disease progression.

Huang X, Fowler C, Li Y, Li Q, Sun J, Pan Y Nat Commun. 2024; 15(1):7998.

PMID: 39266542 PMC: 11393069. DOI: 10.1038/s41467-024-52396-1.


Advances in Blood Biomarkers for Alzheimer's Disease: Ultra-Sensitive Detection Technologies and Impact on Clinical Diagnosis.

Zhang Y, Bi K, Zhou L, Wang J, Huang L, Sun Y Degener Neurol Neuromuscul Dis. 2024; 14:85-102.

PMID: 39100640 PMC: 11297492. DOI: 10.2147/DNND.S471174.


Use of 3D Printing Techniques to Fabricate Implantable Microelectrodes for Electrochemical Detection of Biomarkers in the Early Diagnosis of Cardiovascular and Neurodegenerative Diseases.

Zilinskaite N, Shukla R, Baradoke A ACS Meas Sci Au. 2023; 3(5):315-336.

PMID: 37868357 PMC: 10588936. DOI: 10.1021/acsmeasuresciau.3c00028.


Plasma Biomarkers of Alzheimer's Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice.

Pais M, Forlenza O, Diniz B J Alzheimers Dis Rep. 2023; 7(1):355-380.

PMID: 37220625 PMC: 10200198. DOI: 10.3233/ADR-230029.


The Effects of Extract on Memory Improvement in Those with Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Choi W, Lee W, Kim T, Ryu Y, Park A, Lee Y Nutrients. 2022; 14(18).

PMID: 36145090 PMC: 9505028. DOI: 10.3390/nu14183714.